Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + PD-1 in Recurrent/Metastatic NPC
NCT04350190Phase 2Completed
- Start
- Jan 2021
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and camrelizumab in nasopharyngeal carcinoma (NPC). Primary endpoint: Overall Response Rate up to 24 months. Started Jan 2021; status: completed.
02
Drugs
Rivoceranibcamrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04350190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04350190.